Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19
NCT ID: NCT04406233
Last Updated: 2020-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
176 participants
OBSERVATIONAL
2020-05-23
2022-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Home-based Exercise in COVID-19 Survivors
NCT04615052
Normative Values for Peripheral Muscle Strength in Critical Patients and Healthy Individuals
NCT06296381
Evaluation of Muscle Strength, Functional Independence, Myalgia, Fatigue and Dyspnea in COVID-19 Infection
NCT04784546
Follow-up and Rehabilitation of Survivors of Severe Coronavirus Disease 2019 (COVID-19) Infection
NCT04563156
Low-intensity Aerobic Training Associated With Global Muscle Strengthening in Post-COVID-19
NCT06161740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hospital stay less than 48 hours;
* length of hospital stay to 48 hours no requiring invasive mechanical ventilation;
Exclusion Criteria
* delirium;
* cognitive deficit that impossibility the patient to read and sign the informed consent form;
* neurological disease;
* degenerative muscular disease.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bruno Gualano
Phd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univsersity of Sao Paulo
São Paulo, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
31303720.7.0000.0068
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.